Healthcare Industry News: Stereotactic
News Release - May 2, 2016
Accuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric Image Guidance Solutions for the CyberKnife(R) SystemCollaboration Designed to Expand Clinical Versatility of the CyberKnife® System with Addition of medPhoton Novel Imaging Solution
SUNNYVALE, Calif., May 1, 2016 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that the company has signed an agreement with medPhoton GmbH to collaborate on integration of its ImagingRing® system, a new technology for volumetric image guidance, with the CyberKnife® System. The ImagingRing provides a range of advanced imaging capabilities including large field-of-view cone beam CT. This long-term strategic agreement will provide Accuray with certain exclusive development, sales and distribution rights of the unique ImagingRing for use in adaptive radiation therapy, SBRT and robotic radiosurgery.
"This collaboration with medPhoton enables us to partner with a company which, like ours, is committed to using innovative solutions to improve the lives of cancer patients," said Joshua H. Levine, president and chief executive officer of Accuray. "The Imaging Ring represents the next generation in imaging technology and, together with the CyberKnife System, has the potential to transform the radiation therapy treatment experience for clinicians and their patients."
medPhoton GmbH specializes in the development and manufacturing of sophisticated, state-of-the-art medical equipment in the field of radiotherapy medical imaging. The company is focused on creating high-quality medical devices which make radiotherapy treatments comfortable for patients, while simultaneously improving the radiation oncology team's clinical workflow. medPhoton originated from the Institute for Research and Development on Advanced Radiation Technologies (radART) and the Department for Radiotherapy and Radio-Oncology at the Paracelsus Medical University Clinics Salzburg, leveraging their expertise in application-oriented research and development to design products which address the radiation oncology community's unmet clinical needs.
"The partnership with Accuray provides us with the opportunity to integrate our leading-edge imaging technology with the CyberKnife System, one of the industry's most advanced treatment delivery systems," said Heinz Deutschmann, chief executive officer and founder of medPhoton. "We believe the products will complement each other and enable clinicians to truly optimize the radiation treatments they can provide their patients."
About the CyberKnife System
The CyberKnife M6™ Series delivers radiosurgery and Stereotactic body radiation therapy, enabling precise, high-quality dose distributions to be administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The system is able to adjust and automatically stay on target in real-time, accounting for patient and tumor motion continually throughout the treatment. CyberKnife is the only robotic radiosurgery system available today which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body.
Accuray Incorporated (ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to company growth, market adoption of new technologies, regulatory clearances for new technologies, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015, February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSwiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer